• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: SHANNON COLIN returned 46,500 units of Common Stock to the company, closing all direct ownership in the company

    7/1/21 6:26:22 PM ET
    $PRAH
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $PRAH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    SHANNON COLIN

    (Last) (First) (Middle)
    C/O PRA HEALTH SCIENCES, INC.
    4130 PARKLAKE AVENUE, SUITE 400

    (Street)
    RALEIGH NC 27612

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    PRA Health Sciences, Inc. [ PRAH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President & CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    07/01/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 07/01/2021 D 46,500 D (1)(2) 0 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $75.81 07/01/2021 D 39,000 (3) 08/29/2027 Common Stock 39,000 (7) 0 D
    Stock Option (Right to Buy) $102.44 07/01/2021 D 45,000 (4) 08/16/2028 Common Stock 45,000 (7) 0 D
    Stock Option (Right to Buy) $95.94 07/01/2021 D 62,000 (5) 08/13/2029 Common Stock 62,000 (7) 0 D
    Stock Option (Right to Buy) $103.3 07/01/2021 D 63,560 (6) 06/01/2030 Common Stock 63,560 (7) 0 D
    Restricted Stock Unit (8) 07/01/2021 D 20,974 (9) (9) Common Stock 20,974 (8) 0 D
    Restricted Stock Unit (8) 07/01/2021 D 4,000 (10) (10) Common Stock 4,000 (8) 0 D
    Restricted Stock Unit (8) 07/01/2021 D 52,030 (11) (11) Common Stock 52,030 (8) 0 D
    Explanation of Responses:
    1. Pursuant to the Agreement and Plan of Merger (as it may be amended from time to time) (the "Merger Agreement"), dated as of February 24, 2021, by and among the Issuer, ICON plc ("ICON"), ICON US Holdings Inc. ("US HoldCo") and Indigo Merger Sub, Inc., each share of the Issuer's common stock was converted into the right to receive from ICON, 0.4125 of one ordinary share of ICON, and, from US HoldCo, $80.00 in cash, without any interest thereon (collectively, the "Merger Consideration").
    2. Pursuant to the Merger Agreement, each award of restricted stock of the Issuer that is outstanding immediately prior to the effective time of the merger was converted into the right to receive the Merger Consideration.
    3. The option vests in four annual installments, commencing on August 29, 2018 at 20% of the grant in the first two years and 30% of the grant in the remaining two years thereafter.
    4. The option vests in four equal annual installments of 22,500 beginning on August 16, 2019.
    5. The option vests in three equal annual installments of 31,000 beginning on August 13, 2020.
    6. The option vests in three equal annual installments of 31,780 beginning on June 1, 2021.
    7. Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, as of immediately prior to the effective time of the merger was, at the effective time of the merger, converted into an option to purchase a number of ordinary shares of ICON equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option and (ii) 0.788496037 (the "Parent Equity Conversion Ratio") (rounded down to the nearest whole ordinary share of ICON), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Parent Equity Conversion Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions (including vesting conditions) applicable to such Issuer stock option.
    8. Pursuant to the Merger Agreement, each outstanding award of restricted stock units of the Issuer as of immediately prior to the effective time of the merger was, at the effective time of the merger, converted into a number of restricted stock units of ICON equal to the product of (i) the number of restricted stock units of the Issuer and (ii) the Parent Equity Conversion Ratio, rounded down to the nearest whole ordinary share of ICON, subject to the same terms and conditions (including vesting conditions) applicable to such Issuer restricted stock units.
    9. Restricted stock units convert into the Issuer's common stock on a one-for one basis in an amount equal to one-third of the total amount per year on each anniversary of June 1, 2020, the grant date, subject to the holder's continued service through each vesting date.
    10. Restricted stock units convert into the Issuer's common stock on a one-for one basis in an amount equal to 50% of the total amount per year on each anniversary of June 1, 2020, the grant date, subject to the holder's continued service through each vesting date.
    11. Restricted stock units convert into the Issuer's common stock on a one-for-one basis in an amount equal to one-third of the total amount per year on each anniversary of June 1, 2021, the grant date, subject to the holder's continued service through each vesting date
    By: /s/ Michael J. Bonello, by power of attorney 07/01/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PRAH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRAH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRAH
    SEC Filings

    See more
    • SEC Form S-8 POS filed by PRA Health Sciences, Inc.

      S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)

      7/1/21 9:48:41 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 POS filed by PRA Health Sciences, Inc.

      S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)

      7/1/21 9:45:04 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 POS filed by PRA Health Sciences, Inc.

      S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)

      7/1/21 9:47:14 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PRAH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board

      Believes Incumbent Board's Approval and Ongoing Pursuit of Reckless and Dilutive Proposed Merger with Akoya Biosciences Demonstrates Urgent Need for Refreshment Nominees Would Bring Deep Healthcare and Financial Experience Necessary to Properly Oversee a Standalone Quanterix, Prevent Further Capital Misallocation and Improve Shareholder Value Kent Lake Urges Shareholders to Vote Against Merger with Akoya to Protect the Future Value of Their Investment Kent Lake PR LLC ("Kent Lake"), a holder of 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), announced today it has nominated three highly qualified, independent candidates for e

      3/3/25 8:00:00 AM ET
      $AKYA
      $CMBM
      $CSCO
      $DOMO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Radio And Television Broadcasting And Communications Equipment
      Technology
    • DT Midstream Set to Join S&P MidCap 400

      NEW YORK, June 28, 2021 /PRNewswire/ -- DT Midstream Inc. (NYSE:DTM) will replace PRA Health Sciences Inc. (NASD: PRAH) in the S&P MidCap 400 effective prior to the open on Friday, July 2. ICON plc (NASD: ICLR) is acquiring PRA Health Sciences in a deal expected to be completed soon pending final closing conditions. S&P 500 constituent DTE Energy Co. (NYSE:DTE) is spinning off DT Midstream in a transaction expected to be effective prior to the open on Thursday, July 1. Post spin-off, DTE Energy will remain in the S&P 500.   Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker

      6/28/21 6:07:00 PM ET
      $SPGI
      $DTE
      $ICLR
      $PRAH
      Finance: Consumer Services
      Finance
      Electric Utilities: Central
      Utilities
    • Veradigm and PRA Health Sciences Partner to Create the Industry's Leading EHR-Based Clinical Research Network

      Through this strategic partnership, the network aims to reach more than 25,000 physicians and 40 million patients, accelerating trial recruitment and enrollment efforts and expanding patients' access to clinical research Veradigm®, a leading provider of healthcare data and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ:MDRX), and PRA Health Sciences, Inc. (NASDAQ:PRAH), one of the world's leading global contract research organizations, announced today the creation of the industry's leading electronic healthcare records-based clinical research network that reaches more than 25,000 physicians and 40 million patients across the United States. This press re

      6/23/21 8:01:00 AM ET
      $PRAH
      $MDRX
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      EDP Services
      Technology

    $PRAH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Gaenzle Christopher L returned 34,500 units of Common Stock to the company, closing all direct ownership in the company

      4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

      7/1/21 6:29:52 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: SHANNON COLIN returned 46,500 units of Common Stock to the company, closing all direct ownership in the company

      4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

      7/1/21 6:26:22 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Bonello Michael J. returned 4,480 units of Common Stock to the company, closing all direct ownership in the company

      4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

      7/1/21 5:47:14 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PRAH
    Leadership Updates

    Live Leadership Updates

    See more
    • Anavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of Directors

      Strengthening Board of Directors with Expertise in Innovative Product Launches NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Ms. Jiong Ma, PhD to its Board of Directors. Ms. Ma is Senior Board executive with over 25 years of experience in investing, building, scaling of companies with focus on innovative product launches in

      5/26/21 7:00:00 AM ET
      $AVXL
      $TMDX
      $PRAH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Commercial Physical & Biological Resarch

    $PRAH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PRA Health Sciences, Inc.

      SC 13G - PRA Health Sciences, Inc. (0001613859) (Subject)

      7/12/21 4:27:12 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by PRA Health Sciences, Inc. (Amendment)

      SC 13G/A - PRA Health Sciences, Inc. (0001613859) (Subject)

      7/12/21 10:21:51 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by PRA Health Sciences, Inc. (Amendment)

      SC 13G/A - PRA Health Sciences, Inc. (0001613859) (Subject)

      4/12/21 2:07:51 PM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PRAH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PRA Health Sciences downgraded by Truist with a new price target

      Truist downgraded PRA Health Sciences from Buy to Hold and set a new price target of $175.00 from $196.00 previously

      5/10/21 7:22:17 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Credit Suisse reiterated coverage on PRA Health Sciences with a new price target

      Credit Suisse reiterated coverage of PRA Health Sciences with a rating of Outperform and set a new price target of $169.00 from $159.00 previously

      4/29/21 10:40:10 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PRA Health Sciences downgraded by Baird with a new price target

      Baird downgraded PRA Health Sciences from Outperform to Neutral and set a new price target of $165.00

      4/20/21 7:51:16 AM ET
      $PRAH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care